Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2
Annals of Biomedical Engineering · 2024
DOI: 10.1007/s10439-024-03478-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Biomedical Engineering, 2024. Verfasst von Cara O'Mahoney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Clemson University, Clemson, SC, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Angiotensin-Converting Enzyme 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clemson University.
Abstract (Originalsprache)
SARS-CoV-2 has rampantly spread around the globe and continues to cause unprecedented loss through ongoing waves of (re)infection. Increasing our understanding of the protection against infection with SARS-CoV-2 is critical to ending the pandemic. Serological assays have been widely used to assess immune responses, but secretory antibodies, the essential first line of defense, have been studied to only a limited extent. Of particular interest and importance are neutralizing antibodies, which block the binding of the spike protein of SARS-CoV-2 to the human receptor angiotensin-converting enzyme-2 (ACE2) and thus are essential for immune defense. Here, we employed Microfluidic Diffusional Sizing (MDS), an immobilization-free technology, to characterize neutralizing antibody affinity to SARS-CoV-2 spike receptor-binding domain (RBD) and spike trimer in saliva. Affinity measurement was obtained through a contrived sample and buffer using recombinant SARS-CoV-2 RBD and monoclonal antibody. Limited saliva samples demonstrated that MDS applies to saliva neutralizing antibody measurement. The ability to disrupt a complex of ACE2-Fc and spike trimer is shown. Using a quantitative assay on the patient sample, we determined the affinity and binding site concentration of the neutralizing antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Clemson University, Clemson, SC, USA.
- Fluidic Analytics, Cambridge, UK.
- Center for Innovative Medical Devices and Sensors, Clemson University, Clemson, SC, USA.
- Department of Bioengineering, Clemson University, Clemson, SC, USA. congyup@clemson.edu.
- Center for Innovative Medical Devices and Sensors, Clemson University, Clemson, SC, USA. congyup@clemson.edu.
Förderung
- Clemson University
Zitieren
APA
O'Mahoney, C., Watt, I., Fiedler, S., Devenish, S., Srikanth, S., Justice, E., Dover, T., Dean, D., & Peng, C. (2024). Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-024-03478-0
Vancouver
O'Mahoney C, Watt I, Fiedler S, Devenish S, Srikanth S, Justice E, et al. Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2. Annals of Biomedical Engineering. 2024. doi:10.1007/s10439-024-03478-0
BibTeX
@article{OMahoney2024,
author = {O'Mahoney, Cara and Watt, Ian and Fiedler, Sebastian and Devenish, Sean and Srikanth, Sujata and Justice, Erica and Dover, Tristan and Dean, Delphine and Peng, Congyue},
title = {Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2},
journal = {Annals of Biomedical Engineering},
year = {2024},
doi = {10.1007/s10439-024-03478-0}
}
EUVIMED